Pfizer Booster Shot Recommended by CDC

booster shot
CDC Recommends Pfizer Booster Shot for Certain Individuals

What You Need to Know

CDC recommends that the following groups should receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series (i.e., the first 2 doses of a COVID-19 vaccine):

  • people aged 65 years and older
  • residents aged 18 years and older in long-term care settings
  • people aged 50–64 years with underlying medical conditions

CDC also recommends that the following groups may receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series, based on their individual benefits and risks:

  • people aged 18–49 years with underlying medical conditions
  • people aged 18–64 years at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting

These recommendations only apply to people who previously received a Pfizer-BioNTech primary series (i.e., the first 2 doses of a COVID-19 vaccine).

People can talk to their healthcare provider about whether getting a Pfizer-BioNTech COVID-19 booster shot is appropriate for them.

Data Supporting Need for a Booster Shot

Studies show that after getting vaccinated against COVID-19, protection against the virus may decrease over time and be less able to protect against the Delta variant. Although COVID-19 vaccination for adults aged 65 years and older remains effective in preventing severe disease, recent data suggest vaccination is less effective at preventing infection or milder illness with symptoms. Emerging evidence also shows that among healthcare and other frontline workers, vaccine effectiveness against COVID-19 infections is decreasing over time. This lower effectiveness is likely due to the combination of decreasing protection as time passes since getting vaccinated (e.g., waning immunity) as well as the greater infectiousness of the Delta variant.

Data from a small clinical trial show that a Pfizer-BioNTech booster shot increased the immune response in trial participants who finished their primary series 6 months earlier. With an increased immune response, people should have improved protection against COVID-19, including the Delta variant.

For more information, please click here: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html